WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq:NURO) announced that it was the recipient of
the Smaller Businesses Association of New England (SBANE) New England
Innovation Award for the development and successful launch of Quell®
Wearable Pain Relief Technology™. Previous winners of this prestigious
award include iRobot, Staples, Ben & Jerry's and HubSpot along with 209
other past winners since 1986.
"We are excited that our innovative technology has been recognized,"
said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix.
"With 100 million Americans suffering pain, and a high level of consumer
dissatisfaction with current treatments such as prescription opioids,
Quell is an innovation that is making a meaningful difference in
The Smaller Business Association of New England,
Inc. (SBANE), founded in 1938, is a private not-for-profit association
of approximately 600 member companies located throughout the six-state
region. SBANE was established to provide a legislative voice for small
business at the state and federal levels and to make practical
information available to help business owners grow their companies.
Quell is designed for millions of people
suffering from chronic pain. The advanced wearable device is lightweight
and can be worn during the day while active, and at night while
sleeping. It has been cleared by the FDA for treatment of chronic pain
without a prescription. In a recent study, 81% of Quell users reported
an improvement in their chronic pain. Quell users can personalize and
manage therapy discreetly via the Quell Relief app. Quell also offers
advanced health tracking relevant to chronic pain sufferers including
pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW
(South by Southwest) Innovation Award for Best Wearable Technology.
Quell is available at select healthcare professionals and retailers.
for more information.
NeuroMetrix is a commercial stage,
innovation driven healthcare company combining bioelectrical and digital
medicine to address chronic health conditions including chronic pain,
sleep disorders, and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain. Quell is
integrated into a digital health platform that helps patients optimize
their therapy and decrease the impact of chronic pain on their quality
of life. The company also markets DPNCheck®, a rapid
point-of-care test for diabetic neuropathy, which is the most common
long-term complication of Type 2 diabetes. The company maintains an
active research effort and has several pipeline programs. The company is
located in Waltham, Massachusetts and was founded as a spinoff from the
Harvard-MIT Division of Health Sciences and Technology in 1996. For more
information, please visit NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005180/en/
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
Source: NeuroMetrix, Inc.
News Provided by Acquire Media